As per the terms of the agreement, OctoPlus is expected to perform process development and clinical manufacturing for The Medicines Company related to MDCO-216 (ApoA-I Milano/phospholipid complex).
MDCO-216 is a naturally occurring variant of a protein found in human high-density lipoprotein (HDL). Based upon multiple non-clinical studies and a Phase 1/2 clinical trial of MDCO-216 conducted prior to the exclusive license obtained by The Medicines Company in December 2009, MDCO-216 is believed to have the potential to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS.
OctoPlus is a European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.